Delveinsight's Extensive Coverage of
ESMO 2023 Conference

Tarlatamab at 10 mg reveals enduring anticancer efficacy with a well-managed safety profile. These findings endorse the utilization of tarlatamab in individuals with previously treated SCLC.

Dato-DXd marks a groundbreaking achievement as the first ADC to exhibit a statistically significant enhancement in PFS compared to docetaxel in individuals with previously treated, locally advanced, or metastatic NSCLC. This positions Dato-DXd as a promising and meaningful therapeutic option for patients with a history of non-squamous NSCLC who have undergone prior treatments

ALECENSA (alectinib) exhibits notable effectiveness in the treatment of ALK-positive non-small cell lung cancer (NSCLC), especially among Asians with resected stage IB–IIIA disease. The ALINA trial demonstrates enhanced disease-free survival (DFS) and central nervous system (CNS) protection, affirming its status as a preferred choice for both first-line and adjuvant treatment.

Milademetan and trabectedin exhibit comparable median progression-free survival (PFS) based on BICR assessment, revealing no significant distinction. Milademetan maintains a consistent safety profile, with no new signals detected. Uncovering the patient cohort poised to benefit most from milademetan requires additional investigation.

Recurrent Clear Cell Gynecologic Cancers (CCGC) often exhibit low response rates to chemotherapy or durvalumab alone. The LARA trial, the first of its kind globally and in Asia, explores the efficacy of a PD-1 inhibitor with a multi-kinase inhibitor in ovarian clear cell carcinoma. Preliminary findings from the trial suggest promising efficacy of this combination in pre-treated advanced clear cell gynecological cancer patients.

The clinical application of PD-1 immunotherapy faces challenges due to limited patient response rates and high rates of immune-related adverse effects. Radiation therapy has shown potential in enhancing PD-1 efficiency by inducing tumor antigens, modifying the tumor microenvironment, and increasing PD-L1 expression on tumors. The optimal sequence for this combined treatment strategy remains uncertain.